Lauren T Roland1, Timothy L Smith2, Rodney J Schlosser3, Zachary M Soler3, Anju T Peters4, Tanya M Laidlaw5, Benjamin S Bleier6, Vijay Ramakrishnan7, Elina Toskala8, David W Kennedy9, Amber U Luong10. 1. Department of Otolaryngology, University of California, San Francisco, CA. 2. Department of Otolaryngology, Oregon Health and Science University, Portland, OR. 3. Department of Otolaryngology, Medical University of South Carolina, Charleston, SC. 4. Division of Allergy-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL. 5. Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 6. Department of Otolaryngology, Harvard Medical School, Boston, MA. 7. Department of Otolaryngology, University of Colorado, Aurora, CO. 8. Department of Otolaryngology, Thomas Jefferson University, Philadelphia, PA. 9. Department of Otolaryngology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 10. Department of Otolaryngology, Head and Neck Surgery, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX.
Abstract
BACKGROUND: Biologic medications are emerging as options for treating chronic rhinosinusitis with nasal polyps (CRSwNP). Several questions remain regarding patient selection, indications, clinical efficacy, and cost effectiveness. METHODS: In November 2019, a group of physicians and scientists gathered to consider strategies for future studies regarding biologics. During the discussion, gaps in knowledge highlighted a need for a consensus on the present day use of biologics in polyp patients. RESULTS: The goal of this guideline is to propose recommendations for the current use of biologics in CRSwNP as new evidence continues to emerge and inform practice. CONCLUSION: We suggest that physicians evaluate patients on an individual basis and closely monitor for improvement due to the high cost and unknown long-term effects of biologics.
BACKGROUND: Biologic medications are emerging as options for treating chronic rhinosinusitis with nasal polyps (CRSwNP). Several questions remain regarding patient selection, indications, clinical efficacy, and cost effectiveness. METHODS: In November 2019, a group of physicians and scientists gathered to consider strategies for future studies regarding biologics. During the discussion, gaps in knowledge highlighted a need for a consensus on the present day use of biologics in polyp patients. RESULTS: The goal of this guideline is to propose recommendations for the current use of biologics in CRSwNP as new evidence continues to emerge and inform practice. CONCLUSION: We suggest that physicians evaluate patients on an individual basis and closely monitor for improvement due to the high cost and unknown long-term effects of biologics.
Authors: Zachary M Soler; Rodney J Schlosser; Todd E Bodner; Jeremiah A Alt; Vijay R Ramakrishnan; Jose L Mattos; Jennifer K Mulligan; Jess C Mace; Timothy L Smith Journal: J Allergy Clin Immunol Date: 2021-02-04 Impact factor: 10.793
Authors: Timothy L Smith; Rodney J Schlosser; Zachary M Soler; Jess C Mace; Jose L Mattos; Vijay R Ramakrishnan; Daniel M Beswick; Jeremiah A Alt; Jennifer K Mulligan Journal: Int Forum Allergy Rhinol Date: 2021-02-24 Impact factor: 5.426